# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Non-squamous non-small cell lung cancer, KRAS G12C fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet therapy (NHS England policy) or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) (NHS England policy) or
* pemetrexed and carboplatin (NHS England policy) or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had initial treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy) or
* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) or with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or who have had pemetrexed maintenance, and who have had disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.